The anti-
tumor activity of the putative differentiation-inducing agent
dimethylformamide (DMF) was assessed in 7 head-and-neck xenograft (HNX) lines transplanted into nude mice. The
drug was administered intra-peritoneally at the maximum tolerated dose. A significant growth-inhibitory effect was observed in 3 out of 7
tumor lines tested. When compared with 5 conventional drugs active in patients with
squamous-cell carcinoma of the head and neck (
HNSCC), DMF was as effective as the most active drugs (
cisplatin and
bleomycin). The most sensitive xenograft line, the poorly differentiated
tumor HNX-14C, was used to test the hypothesis that differentiation induction might play a role in the anti-
tumor activity of DMF. Light microscopic examination did not show clear-cut alteration of differentiation characteristics such as
keratin and
keratin pearl formation. Furthermore, we used a
monoclonal antibody to study the expression of
cytokeratin 10 which is useful as a
differentiation marker of human
HNSCC tumors.
Keratin 10, not present in HNX-14C
tumors grown under control conditions, became expressed in some cells upon DMF treatment. Further evidence for a differentiation-inducing activity of DMF was found in electron-microscopic studies. In treated HNX-14C
tumors, in addition to cells with normal ultrastructural features, better-differentiated cells were observed, as manifested by an increase in the number of tonofilaments and desmosomes. The results show that DMF has a potential value for the treatment of patients with
head-and-neck cancer, and that differentiation induction might play a role in the anti-
tumor action of the
drug.